Cargando…

(68)Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging

PURPOSE: For the tumor-specific ACE2 expression, this research aimed to establish and verify ACE2-targeted PET imaging in differentiating tumors with distinct ACE2 expression. METHODS: (68)Ga-cyc-DX600 was synthesized as tracer of ACE2 PET. NOD-SCID mice were used to prepare the subcutaneous tumor m...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Fangyuan, Jiang, Hongyang, Shi, Lin, Zhang, Lan, Li, Xiao, Lu, Qinkang, Li, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969023/
https://www.ncbi.nlm.nih.gov/pubmed/36847824
http://dx.doi.org/10.1007/s00259-023-06159-7
_version_ 1784897629796171776
author Ren, Fangyuan
Jiang, Hongyang
Shi, Lin
Zhang, Lan
Li, Xiao
Lu, Qinkang
Li, Qiang
author_facet Ren, Fangyuan
Jiang, Hongyang
Shi, Lin
Zhang, Lan
Li, Xiao
Lu, Qinkang
Li, Qiang
author_sort Ren, Fangyuan
collection PubMed
description PURPOSE: For the tumor-specific ACE2 expression, this research aimed to establish and verify ACE2-targeted PET imaging in differentiating tumors with distinct ACE2 expression. METHODS: (68)Ga-cyc-DX600 was synthesized as tracer of ACE2 PET. NOD-SCID mice were used to prepare the subcutaneous tumor models with HEK-293 or HEK-293T/hACE2 cells to verify ACE2 specificity, with other kinds of tumor cells to evaluate the diagnostic efficiency for ACE2 expression, additionally, immunohistochemical analysis and western blot were used to certify the findings on ACE2 PET, which was then performed on four cancer patients and compared with FDG PET. RESULTS: The metabolic clearance of (68)Ga-cyc-DX600 was initially completed in 60 min, realizing an ACE2-dependent and organ-specific background of ACE2 PET; meanwhile, tracer uptake of subcutaneous tumor models was of a definite dependence on ACE2 expression (r = 0.903, p < 0.05), and the latter served as the primary factor when ACE2 PET was used for the differential diagnosis of ACE2-related tumors. In pre-clinical practice, a comparable tumor-to-background ratio was acquired in ACE2 PET of a lung cancer patient at 50 and 80 min post injection; the quantitative values of ACE2 PET and FDG PET were negatively correlated (r =  − 0.971 for SUV(max), p = 0.006; r =  − 0.994 for SUV(mean), p = 0.001) in an esophageal cancer patient, no matter the primary lesion or metastasis. CONCLUSIONS: (68)Ga-cyc-DX600 PET was an ACE2-specific imaging for the differential diagnosis of tumors and added complementary value to conventional nuclear medicine diagnosis, such as FDG PET on glycometabolism.
format Online
Article
Text
id pubmed-9969023
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-99690232023-02-28 (68)Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging Ren, Fangyuan Jiang, Hongyang Shi, Lin Zhang, Lan Li, Xiao Lu, Qinkang Li, Qiang Eur J Nucl Med Mol Imaging Original Article PURPOSE: For the tumor-specific ACE2 expression, this research aimed to establish and verify ACE2-targeted PET imaging in differentiating tumors with distinct ACE2 expression. METHODS: (68)Ga-cyc-DX600 was synthesized as tracer of ACE2 PET. NOD-SCID mice were used to prepare the subcutaneous tumor models with HEK-293 or HEK-293T/hACE2 cells to verify ACE2 specificity, with other kinds of tumor cells to evaluate the diagnostic efficiency for ACE2 expression, additionally, immunohistochemical analysis and western blot were used to certify the findings on ACE2 PET, which was then performed on four cancer patients and compared with FDG PET. RESULTS: The metabolic clearance of (68)Ga-cyc-DX600 was initially completed in 60 min, realizing an ACE2-dependent and organ-specific background of ACE2 PET; meanwhile, tracer uptake of subcutaneous tumor models was of a definite dependence on ACE2 expression (r = 0.903, p < 0.05), and the latter served as the primary factor when ACE2 PET was used for the differential diagnosis of ACE2-related tumors. In pre-clinical practice, a comparable tumor-to-background ratio was acquired in ACE2 PET of a lung cancer patient at 50 and 80 min post injection; the quantitative values of ACE2 PET and FDG PET were negatively correlated (r =  − 0.971 for SUV(max), p = 0.006; r =  − 0.994 for SUV(mean), p = 0.001) in an esophageal cancer patient, no matter the primary lesion or metastasis. CONCLUSIONS: (68)Ga-cyc-DX600 PET was an ACE2-specific imaging for the differential diagnosis of tumors and added complementary value to conventional nuclear medicine diagnosis, such as FDG PET on glycometabolism. Springer Berlin Heidelberg 2023-02-27 2023 /pmc/articles/PMC9969023/ /pubmed/36847824 http://dx.doi.org/10.1007/s00259-023-06159-7 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Ren, Fangyuan
Jiang, Hongyang
Shi, Lin
Zhang, Lan
Li, Xiao
Lu, Qinkang
Li, Qiang
(68)Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging
title (68)Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging
title_full (68)Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging
title_fullStr (68)Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging
title_full_unstemmed (68)Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging
title_short (68)Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging
title_sort (68)ga-cyc-dx600 pet/ct in ace2-targeted tumor imaging
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969023/
https://www.ncbi.nlm.nih.gov/pubmed/36847824
http://dx.doi.org/10.1007/s00259-023-06159-7
work_keys_str_mv AT renfangyuan 68gacycdx600petctinace2targetedtumorimaging
AT jianghongyang 68gacycdx600petctinace2targetedtumorimaging
AT shilin 68gacycdx600petctinace2targetedtumorimaging
AT zhanglan 68gacycdx600petctinace2targetedtumorimaging
AT lixiao 68gacycdx600petctinace2targetedtumorimaging
AT luqinkang 68gacycdx600petctinace2targetedtumorimaging
AT liqiang 68gacycdx600petctinace2targetedtumorimaging